Difference between revisions of "MSK Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
 
(11 intermediate revisions by the same user not shown)
Line 9: Line 9:
  
 
'''Approved call summaries:'''
 
'''Approved call summaries:'''
*[[Media:2021_02-23_QIBA_MSK_BC_Call_Summary-FINAL.pdf|February 23, 2021]]
+
*[[Media:2022-05-24_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|May 24, 2022]]
*[[Media:2021_01-26_QIBA_MSK_BC_Call_Summary-FINAL.pdf|January 26, 2021]]
+
*[[Media:2022-04-26_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|April 26, 2022]]
*[[Media:2020_10-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|October 27, 2020]]
+
*[[Media:2022-03-22_QIBA_MSK_BC_Meeting_Summary-FINAL.pdf|March 22, 2022]]
  
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
 
'''''[[MSK Biomarker Committee Call Summaries Archive]]'''''
  
==Working Documents==
+
==Profile Documents==
*[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx| QIBA MSK Profile 2020-01-28:]] ''MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease''
+
*[[Media:QIBA_Profile_MSK-Cartilage-Stage2_Profile.pdf|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2021-09-25 - Consensus Profile]]
 +
*[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx|MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease 2020-01-28 - Public Comment Profile]]
  
 
==Statistical Reference Documents==
 
==Statistical Reference Documents==

Latest revision as of 16:10, 28 June 2022